Uncomplicated Urinary Tract Infection Market Report 2026

The uncomplicated urinary tract infection market size has grown strongly in recent years. It will grow from $10.95 billion in 2025 to $11.69 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of urinary tract infections, widespread use of laboratory-based diagnostics, availability of broad-spectrum antibiotics, expansion of hospital diagnostic infrastructure, growing awareness of infection management.

The uncomplicated urinary tract infection market size is expected to see strong growth in the next few years. It will grow to $15.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to increasing demand for rapid and accurate diagnostics, rising focus on reducing antibiotic resistance, expansion of molecular diagnostic techniques, growing adoption of point-of-care testing solutions, increasing investments in laboratory automation. Major trends in the forecast period include increasing use of rapid diagnostic testing methods, rising adoption of automated urinalysis systems, growing focus on antimicrobial stewardship programs, expansion of point-of-care uti diagnostics, enhanced emphasis on early infection detection.

The rising incidence of chronic kidney diseases is expected to drive the growth of the uncomplicated urinary tract infection market going forward. Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose function, causing waste and fluid to accumulate in the body. The increasing prevalence of CKD is primarily driven by the growing number of diabetes cases. Prolonged high blood sugar levels can damage the kidneys, reducing their ability to filter waste efficiently. CKD weakens the immune system, making individuals more vulnerable to urinary tract infections, and poor kidney function leads to urine retention, creating an environment conducive to bacterial growth. For instance, in June 2023, according to a report released by Kidney Research UK, a UK-based non-profit organization, around 7.2 million people in the UK are currently living with chronic kidney disease, accounting for more than 10% of the population. Among these individuals, 3.25 million are in the advanced stages of the disease, while a further 3.9 million are in the early stages. By 2033, the number of people affected by chronic kidney disease is expected to increase to 7.61 million. Therefore, the rising incidence of chronic kidney diseases is propelling the uncomplicated urinary tract infection market.

Increasing cases of diabetes are expected to further drive the growth of the uncomplicated urinary tract infection market. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels caused by insufficient insulin production or ineffective insulin utilization. The rise in diabetes cases is linked to unhealthy lifestyle choices, including poor diet and lack of physical activity. High consumption of processed and sugar-rich foods, along with sedentary habits, has led to higher obesity rates, a major risk factor for type 2 diabetes. Elevated blood sugar levels create favorable conditions for bacterial growth in the urinary tract, increasing the prevalence of infections. Additionally, diabetes can compromise the immune system, making it harder for the body to fight infections, including UTIs. For instance, in March 2024, according to the Office for Health Improvement & Disparities (OHID), a UK-based government body, the percentage of individuals with Type 1 diabetes in England receiving all eight care processes increased from 35.2% to 43.8% in just one year. Therefore, the rising prevalence of diabetes is driving the growth of the uncomplicated urinary tract infection market.

Leading companies in the uncomplicated urinary tract infection (UTI) market are focusing on developing antibiotics to improve treatment effectiveness and address antibiotic-resistant bacteria. Antibiotics are medications that treat bacterial infections by killing bacteria or inhibiting their growth. For example, in April 2024, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for treating adult females with uncomplicated urinary tract infections. These tablets are intended for UTIs caused by susceptible Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus isolates. Pivmecillinam is a prodrug that converts to mecillinam, a beta-lactam antibiotic that targets gram-negative bacteria by inhibiting bacterial cell wall synthesis.

Major companies operating in the uncomplicated urinary tract infection market are Pfizer Inc., Bayer AG, GSK plc, Shionogi & Co. Ltd., Cipla Inc., Orchid Pharma Limited, Iterum Therapeutics PLC, UTILITY Therapeutics Ltd., Siemens AG, Sysmex Corporation, Bio-Rad Laboratories Inc., ACON Labs, Novartis AG, Sanofi SA, AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Roche Holding AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the uncomplicated urinary tract infection market in 2025. The regions covered in the uncomplicated urinary tract infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uncomplicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the uncomplicated urinary tract infection market by increasing costs of imported diagnostic reagents, laboratory instruments, testing consumables, and automated analysis systems used in urinalysis and culture testing. Hospitals and diagnostic laboratories in North America and Europe are most affected due to dependence on imported diagnostic technologies, while Asia-Pacific faces cost pressures on reagent manufacturing. These tariffs are raising testing costs and slowing equipment upgrades. At the same time, they are encouraging domestic reagent production, localized diagnostic manufacturing, and regional supply chain strengthening for essential infection testing solutions.

The uncomplicated urinary tract infection market research report is one of a series of new reports that provides uncomplicated urinary tract infection market statistics, including uncomplicated urinary tract infection industry global market size, regional shares, competitors with a uncomplicated urinary tract infection market share, detailed uncomplicated urinary tract infection market segments, market trends and opportunities, and any further data you may need to thrive in the uncomplicated urinary tract infection industry. This uncomplicated urinary tract infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An uncomplicated urinary tract infection (UTI) is a bacterial infection of the bladder or urethra that commonly occurs in healthy individuals without structural abnormalities or underlying conditions. It usually affects the bladder (cystitis) and is caused by common uropathogens, such as Escherichia coli (E. coli). The primary goal of diagnosis and treatment is to relieve symptoms, prevent complications, and eradicate the infection using short-course antibiotics, ensuring a quick recovery without lasting effects.

The main types of tests in the uncomplicated urinary tract infection market include urinalysis, urine cultures, and susceptibility testing. Urinalysis is a laboratory test that examines a urine sample to detect and measure various substances, including proteins, glucose, red and white blood cells, and bacteria. The commonly used drugs include penicillin and its combinations, quinolones, cephalosporins, azoles and amphotericin B, nitrofurans, and others. These treatments are utilized by various end-users, including hospitals, diagnostic laboratories, and research institutes.

The uncomplicated urinary tract infection market consists of sales of urinary analgesics, pH-altering agents, and hydration and supportive supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.